Video

Dr. Pecora on the CPIT001 Study in Hematologic Malignancies

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.

The CPIT001 trial is investigating the safety and efficacy of the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplant in patients with high-risk hematologic malignancies. The first 29 patients enrolled experienced adverse events but those were not unexpected, says Percora.

Related Videos
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Neal D. Shore, MD, FACS
Sheldon M. Feldman, MD
Louis Crain Garrot, MD
Michel Delforge, MD, PhD
Thach-Giao Truong, MD
Aparna Parikh, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec